NK Cells' Role In Non-Viral Approaches To Genetic Engineering

Here, Dr. Robert Hariri, Chairman, founder, and CEO of Celularity, and Paul Kopesky, Ph.D., VP of Cell Therapy Process Development at Beam Therapeutics each share their take on the primary challenge to modifying NK cells. For example, Dr. Hariri discusses the lack of gene engineering tools, and how it is often difficult to virally transduce NK cells due to the absence of certain receptors for the envelope protein like VSVG.